MEDIPOST has submitted an investigational new drug (IND) amendment to the US Food and Drug Administration (FDA) to initiate a ...

VIENNA — The hypothesis that pivotal clinical trials for osteoarthritis (OA)-modifying therapies are not using appropriate designs or endpoints appears to be consistent with the recent failure of the ...

WASHINGTON — Investigational treatments aimed specifically at reducing pain in knee osteoarthritis (OA) are moving forward in parallel with disease-modifying approaches. “We still have very few ...

Apimeds Pharmaceuticals is set to discuss a treatment for osteoarthritis using bee venom at a Type C meeting with the Food and Drug Administration.

The effectiveness of exercise therapy to ease the symptoms of osteoarthritis is likely minimal, short lived, and probably no ...

| DelveInsight The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic ...

The rheumatoid arthritis market is poised for growth due to the rising adoption of advanced disease-modifying therapies, fostering deeper patient retention and consistent demand. Challenges include ...

Osteoarthritis is the leading cause of disability and chronic pain worldwide, affecting an estimated 595 million people globally. Projections suggest that this number will rise to 1 billion by 2050.

A new review from researchers at University of Adelaide has questioned how effective exercise is for osteoarthritis, but ...